Evidence map›Paper›PMID 36904275›Full record

ArticleNutrients2023

Jolita Stabrauskiene, Mindaugas Marksa, Liudas Ivanauskas, Pranas Viskelis, Jonas Viskelis, Jurga Bernatoniene

Full text read
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Naringin vs.Antioxidants (Basel, Switzerland) · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jolita StabrauskieneDepartment of Drug Technology and Social Pharmacy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.ORCID 0000-0002-0721-3995
Mindaugas MarksaDepartment of Analytical and Toxicological Chemistry, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.ORCID 0000-0001-6934-9524
Liudas IvanauskasDepartment of Analytical and Toxicological Chemistry, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.ORCID 0000-0001-5390-2161
Pranas ViskelisLithuanian Research Centre for Agriculture and Forestry, Institute of Horticulture, LT-54333 Babtai, Lithuania.ORCID 0000-0001-5546-0168
Jonas ViskelisLithuanian Research Centre for Agriculture and Forestry, Institute of Horticulture, LT-54333 Babtai, Lithuania.ORCID 0000-0002-1074-8384
Jurga BernatonieneDepartment of Drug Technology and Social Pharmacy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.ORCID 0000-0003-1744-2932

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Citrus fruits have been the subject of extensive research over the years due to their impressive antioxidant properties, the health benefits of flavanones, and their potential use in the prevention and treatment of chronic diseases. Grapefruit have been shown in studies to improve overall health, with numerous potential benefits, including improved heart health, reduced risk of certain cancers, improved digestive health, and improved immune system function. The development of cyclodextrin complexes is an exciting approach to increasing the content of flavanones such as naringin and naringenin in the extraction medium while improving the profile of beneficial phenolic compounds and the antioxidant profile. This research aims to optimize the extraction conditions of the flavanones naringin and naringenin with additional compounds to increase their yield from different parts of grapefruit (

Indexed as

CitrusCitrus paradisiFlavanonesAntioxidantsFlavonoidsFruitPhenolsPhytochemicalsAntioxidantsFlavanonesFlavonoidsPhenolsPhytochemicalsaglyconesantioxidantCitrus × paradisi L.cyclodextrinsexcipientsextractionsflavanonesgrapefruit

Identifiers

PMID36904275
PMCPMC10005199

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read2
measurements read129
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.